teriflunomide,ublituximab
tg therapeutics,sanofi
['ease', 'ublituximab', 'aubagio', 'teriflunomide', 'imab ', '$tgtx']
disease outcomes with ublituximab in treatment-naive participants:
an adjusted annualised relapse rate (arr) of 0.081 (#ublituximab) and 0.188 (#teriflunomide) (p&lt;0.0001)
aubagio (teriflunomide) sales decreased 1.9% in the 4th q21 to 478million $tgtx 
Master of Disaster ;-)